Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01789606 · ClinicalTrials.gov registry record · Phase 3
Self-Selection and Actual Use Trial of Ibuprofen 600 mg Immediate Release/Extended Caplet
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,083
- Enrollment target
NCT01789606 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 1,083 participants.
The verdict
NCT01789606, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,083 participants
- Enrollment target
Study Summary
A self-selection and actual use trial to evaluate the extent to which consumers will appropriately select and use the 600 mg immediate release/extended release caplets and comply with dosing instructions.
Interventions
- DRUG Ibuprofen 600 mg Immediate Release/Extended Release Caplet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,083 participants |
| Start Date | 2012-09-24 |
| Est. Completion | 2013-06-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01789606
The ClinicalTrials.gov registry entry for NCT01789606 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,083 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ibuprofen 600 mg Immediate Release/Extended Release Caplet is the first listed.
NCT01789606 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01789606 about?
NCT01789606 is a clinical study titled "Self-Selection and Actual Use Trial of Ibuprofen 600 mg Immediate Release/Extended Caplet". A self-selection and actual use trial to evaluate the extent to which consumers will appropriately select and use the 600 mg immediate release/extended release caplets and comply with dosing instructions.
What is the current status of trial NCT01789606?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,083 participants. The study started on 2012-09-24. Estimated completion is 2013-06-03.
What interventions are being tested in trial NCT01789606?
The interventions under investigation include: Ibuprofen 600 mg Immediate Release/Extended Release Caplet (DRUG).
Who is sponsoring clinical trial NCT01789606?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.